Nonetheless, additional studies have also demonstrated a beneficial effect of COX-2 inhibition in the setting of metastatic progression (9), which may present a different risk/benefit calculation, depending on the relative risk of cancer recurrence versus cardiovascular complication. This evidence concerns the gene PTGS2 and cancer.